Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Regeneron records $83M charge for restructuring to boost efficiency and focus on core therapies.

flag Regeneron Pharmaceuticals is set to record an $83 million charge due to a restructuring of its operations, aimed at improving long-term efficiency and focusing on core therapeutic areas. flag The company did not disclose specifics on job cuts or facility closures but said the move supports sustainable growth. flag The one-time expense will impact its current quarter results, though Regeneron remains confident in its pipeline and future performance amid ongoing industry scrutiny over cost management and profitability.

3 Articles